Table 1 Patient, tumor, and treatment characteristics
Characteristic | ||
|---|---|---|
Median age (range) | 67 yr | (39–91 yr) |
Gender: | ||
Male | 70 | (73%) |
Female | 26 | (27%) |
Primary tumor stage: | ||
Stage I | 4 | (4%) |
Stage II | 6 | (6%) |
Stage III | 19 | (20%) |
Stage IV | 60 | (63%) |
Unknown | 7 | (7%) |
Prior definitive therapy: | ||
Radiation only | 9 | (9%) |
Chemo + radiation | 11 | (12%) |
Surgery + radiation | 30 | (31%) |
Chemo, surgery + radiation | 46 | (48%) |
Median prior radiation to head and neck | 70 Gy | (36–139 Gy) |
Median time from prior radiation to first recurrence | 10 mo | (1.4–188 mo) |
Median time from prior radiation to SBRT | 12 mo | (2.4–179 mo) |
Median SBRT dose | 44 Gy | (25–50 Gy) |
Median tumor volume | 26.3 cc | (1–205 cc) |
Use of cetuximab with SBRT | 41 | (43%) |
Patients with other distant or untreated tumors | 40 | (42%) |
Patients treated as adjuvant to surgery | 7 | (7%) |
Sites treated with SBRT: | ||
Oral Cavity | 15 | (16%) |
Nasopharynx | 7 | (7%) |
Oropharynx | 13 | (14%) |
Hypopharynx | 7 | (7%) |
Larynx | 7 | (7%) |
Retropharynx | 5 | (5%) |
Neck | 19 | (20%) |
Base of Skull | 10 | (11%) |
Paranasal Sinuses | 5 | (5%) |
Other | 8 | (8%) |